Ibex Investors LLC Acquires Shares of 13,188 Fluidigm Co. (FLDM)

Ibex Investors LLC acquired a new position in Fluidigm Co. (NASDAQ:FLDM) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 13,188 shares of the medical research company’s stock, valued at approximately $175,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. American International Group Inc. lifted its holdings in Fluidigm by 21.2% during the first quarter. American International Group Inc. now owns 20,946 shares of the medical research company’s stock worth $278,000 after buying an additional 3,661 shares during the period. California Public Employees Retirement System lifted its holdings in Fluidigm by 12.0% during the first quarter. California Public Employees Retirement System now owns 60,906 shares of the medical research company’s stock worth $809,000 after buying an additional 6,506 shares during the period. Sigma Planning Corp purchased a new stake in Fluidigm during the first quarter worth $177,000. Rhumbline Advisers lifted its holdings in Fluidigm by 17.7% during the first quarter. Rhumbline Advisers now owns 40,583 shares of the medical research company’s stock worth $539,000 after buying an additional 6,094 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its holdings in Fluidigm by 3,543.1% during the first quarter. BNP Paribas Arbitrage SA now owns 6,849 shares of the medical research company’s stock worth $91,000 after buying an additional 6,661 shares during the period. 71.44% of the stock is owned by institutional investors.

Shares of FLDM traded up $0.17 during midday trading on Wednesday, hitting $12.20. 6,919 shares of the company’s stock traded hands, compared to its average volume of 634,135. Fluidigm Co. has a 1 year low of $4.65 and a 1 year high of $14.90. The company has a current ratio of 3.26, a quick ratio of 2.86 and a debt-to-equity ratio of 0.30. The firm has a market cap of $793.04 million, a PE ratio of -15.16 and a beta of 2.40.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.30). Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The business had revenue of $30.10 million for the quarter, compared to analysts’ expectations of $29.18 million. The company’s revenue was up 19.4% on a year-over-year basis. As a group, research analysts forecast that Fluidigm Co. will post -0.5 EPS for the current year.

Several analysts have recently commented on the company. Zacks Investment Research lowered Fluidigm from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies increased their price objective on Fluidigm from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. BidaskClub lowered Fluidigm from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. UBS Group assumed coverage on Fluidigm in a report on Friday, March 15th. They set a “neutral” rating and a $14.00 price objective for the company. Finally, BTIG Research assumed coverage on Fluidigm in a report on Wednesday, March 13th. They set a “buy” rating and a $15.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $14.50.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Slater Sentinel and is the property of of Slater Sentinel. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://slatersentinel.com/news/2019/05/15/ibex-investors-llc-acquires-shares-of-13188-fluidigm-co-fldm.html.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Featured Article: What are the qualifications of a portfolio manager?

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.